Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$40.40 USD
+1.94 (5.04%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $40.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
MIRM 40.40 +1.94(5.04%)
Will MIRM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Other News for MIRM
Mirum Pharmaceuticals price target raised by $2 at Leerink, here's why
ClearBridge Small Cap Growth Strategy Q3 2024 Commentary
Analyst Expectations For Mirum Pharmaceuticals's Future
Mirum Pharmaceuticals’ Volixibat Garners Buy Rating Amidst Breakthrough Therapy Designation and Promising Trial Results
Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil